Antibiotics and proton pump inhibitors suppress the efficacy of immunotherapy against non-small cell lung cancer.
作者信息
Diao Xiayao
机构信息
Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
出版信息
Thorac Cancer. 2020 Jul;11(7):1763-1764. doi: 10.1111/1759-7714.13470. Epub 2020 May 6.
Abstract
摘要
相似文献
1
Antibiotics and proton pump inhibitors suppress the efficacy of immunotherapy against non-small cell lung cancer.抗生素和质子泵抑制剂会抑制免疫疗法对非小细胞肺癌的疗效。
Thorac Cancer. 2020 Jul;11(7):1763-1764. doi: 10.1111/1759-7714.13470. Epub 2020 May 6.
2
The association between gut microbiome affecting concomitant medication and the effectiveness of immunotherapy in patients with stage IV NSCLC.肠道微生物群与伴随药物的关联及其对 IV 期 NSCLC 患者免疫治疗效果的影响。
Sci Rep. 2021 Dec 2;11(1):23331. doi: 10.1038/s41598-021-02598-0.
3
[Immuno-checkpoint inhibitor resistance and strategy in lung cancer].[肺癌中的免疫检查点抑制剂耐药性及策略]
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Jul 12;43(7):603-606. doi: 10.3760/cma.j.cn112147-20200312-00319.
4
The role of IL-6 in immunotherapy of non-small cell lung cancer (NSCLC) with immune-related adverse events (irAEs).白细胞介素 6 在免疫相关不良反应（irAEs）的非小细胞肺癌（NSCLC）免疫治疗中的作用。
Thorac Cancer. 2020 Apr;11(4):835-839. doi: 10.1111/1759-7714.13341. Epub 2020 Feb 11.
5
Clinical benefit to programmed death-1 inhibition for non-small-cell lung cancer is associated with higher blood eosinophil levels.程序性死亡-1抑制对非小细胞肺癌的临床益处与较高的血液嗜酸性粒细胞水平相关。
Acta Oncol. 2020 Mar;59(3):257-259. doi: 10.1080/0284186X.2019.1695063. Epub 2019 Nov 22.
6
KEYNOTE-024: Unlocking a pathway to lung cancer cure?KEYNOTE-024：开启肺癌治愈之路？
J Thorac Cardiovasc Surg. 2018 Apr;155(4):1777-1780. doi: 10.1016/j.jtcvs.2017.10.155. Epub 2017 Dec 23.
7
Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors : Antibiotics immune checkpoint inhibitors in advanced NSCLC.晚期非小细胞肺癌患者接受免疫检查点抑制剂治疗时抗生素的预测影响：抗生素免疫检查点抑制剂在晚期 NSCLC 中的应用。
Cancer Chemother Pharmacol. 2020 Jan;85(1):121-131. doi: 10.1007/s00280-019-03993-1. Epub 2019 Nov 19.
8
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020.NCCN 指南解读：非小细胞肺癌，第 1.2020 版。
J Natl Compr Canc Netw. 2019 Dec;17(12):1464-1472. doi: 10.6004/jnccn.2019.0059.
9
There and back again: An immunotherapy tale.往返之间：一个免疫疗法的故事。
J Thorac Cardiovasc Surg. 2018 Apr;155(4):1771-1774. doi: 10.1016/j.jtcvs.2017.11.102. Epub 2017 Dec 23.
10
Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer.免疫疗法在老年非小细胞肺癌患者中的疗效和安全性。
Lung Cancer. 2019 Nov;137:38-42. doi: 10.1016/j.lungcan.2019.08.030. Epub 2019 Sep 10.
引用本文的文献
1
Assessing the impact of probiotics on immunotherapy effectiveness and antibiotic-mediated resistance in cancer: a systematic review and meta-analysis.评估益生菌对癌症免疫治疗效果及抗生素介导耐药性的影响：一项系统综述和荟萃分析。
Front Immunol. 2025 Mar 21;16:1538969. doi: 10.3389/fimmu.2025.1538969. eCollection 2025.
2
Antibiotic adoption effects on nutrition and quality of life in lung cancer patients undergoing radiotherapy and chemotherapy: A meta-analysis.抗生素的采用对放化疗肺癌患者营养和生活质量的影响：一项荟萃分析。
Technol Health Care. 2024;32(6):4515-4536. doi: 10.3233/THC-240660.
3
Concomitant Medications Alter Clinical Outcomes in Patients with Advanced Digestive Tract Cancer Receiving PD-1 Checkpoint Inhibitors Combined with Antiangiogenetic Agents.同时使用的药物会改变接受 PD-1 检查点抑制剂联合抗血管生成药物治疗的晚期消化道癌患者的临床结局。
J Gastrointest Cancer. 2024 Sep;55(3):1388-1400. doi: 10.1007/s12029-024-01095-7. Epub 2024 Jul 30.
4
Association of proton pump inhibitor use with survival and adverse effects outcomes in patients with multiple myeloma: pooled analysis of three clinical trials.质子泵抑制剂的使用与多发性骨髓瘤患者生存和不良反应结局的关联：三项临床试验的汇总分析。
Sci Rep. 2024 Jan 5;14(1):591. doi: 10.1038/s41598-023-48640-1.
5
The Correlation between the Use of the Proton Pump Inhibitor and the Clinical Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.质子泵抑制剂的使用与免疫检查点抑制剂在非小细胞肺癌中的临床疗效之间的相关性
J Oncol. 2022 Jul 9;2022:1001796. doi: 10.1155/2022/1001796. eCollection 2022.
6
Impact of Proton Pump Inhibitors and Histamine-2-Receptor Antagonists on Non-Small Cell Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis.质子泵抑制剂和组胺-2受体拮抗剂对非小细胞肺癌免疫治疗的影响：一项系统评价和荟萃分析
Cancers (Basel). 2022 Mar 9;14(6):1404. doi: 10.3390/cancers14061404.
7
Chronic Use of Proton Pump Inhibitors Is Associated With an Increased Risk of Immune Checkpoint Inhibitor Colitis in Renal Cell Carcinoma.质子泵抑制剂的长期使用与肾细胞癌患者免疫检查点抑制剂相关性结肠炎风险增加相关。
Clin Genitourin Cancer. 2022 Jun;20(3):260-269. doi: 10.1016/j.clgc.2022.01.017. Epub 2022 Feb 1.
8
Investigation of drugs affecting hypertension in bevacizumab-treated patients and examination of the impact on the therapeutic effect.贝伐珠单抗治疗患者影响高血压药物的研究及对疗效影响的考察。
Cancer Med. 2021 Jan;10(1):164-172. doi: 10.1002/cam4.3587. Epub 2020 Nov 24.
本文引用的文献
1
Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials.抗生素和质子泵抑制剂治疗的非小细胞肺癌患者的化疗和阿特珠单抗疗效：OAK 和 POPLAR 试验的汇总事后分析。
Ann Oncol. 2020 Apr;31(4):525-531. doi: 10.1016/j.annonc.2020.01.006. Epub 2020 Jan 16.
2
Immune precision medicine for cancer: a novel insight based on the efficiency of immune effector cells.癌症的免疫精准医学：基于免疫效应细胞效率的新见解。
Cancer Commun (Lond). 2019 Jun 14;39(1):34. doi: 10.1186/s40880-019-0379-3.
3
PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer.非小细胞肺癌中 PD-L1 和 PD-L2 表达相关基因。
Cancer Commun (Lond). 2019 Jun 3;39(1):30. doi: 10.1186/s40880-019-0376-6.
4
Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?中国当前癌症形势：2018 年全球癌症统计数据带来的是好消息还是坏消息？
Cancer Commun (Lond). 2019 Apr 29;39(1):22. doi: 10.1186/s40880-019-0368-6.
5
Cancer statistics, 2019.癌症统计数据，2019 年。
CA Cancer J Clin. 2019 Jan;69(1):7-34. doi: 10.3322/caac.21551. Epub 2019 Jan 8.
6
Comment on the paper 'Boffetta et al. Validation of the diagnosis of mesothelioma and BAP1 protein expression in a cohort of asbestos textile workers from Northern Italy. Ann Oncol 2018; 29(2): 484-489'.
Ann Oncol. 2019 Feb 1;30(2):340-341. doi: 10.1093/annonc/mdy521.
7
Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials.免疫检查点抑制剂与化疗治疗晚期非小细胞肺癌的比较分析：一项随机对照试验的荟萃分析
Medicine (Baltimore). 2018 Aug;97(33):e11936. doi: 10.1097/MD.0000000000011936.
8
Precision medicine becomes reality-tumor type-agnostic therapy.精准医疗成为现实——肿瘤类型不可知的治疗方法。
Cancer Commun (Lond). 2018 Mar 31;38(1):6. doi: 10.1186/s40880-018-0274-3.
9
The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy.肠道微生物组对癌症、免疫和癌症免疫治疗的影响。
Cancer Cell. 2018 Apr 9;33(4):570-580. doi: 10.1016/j.ccell.2018.03.015.
10
The biology and management of non-small cell lung cancer.非小细胞肺癌的生物学特性与治疗管理。
Nature. 2018 Jan 24;553(7689):446-454. doi: 10.1038/nature25183.
Zotero 插件